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a  b  s  t  r  a  c  t
Aim: A literature review was performed to analyse the role of stereotactic radiotherapy given
in  a single shot or in a fractionated fashion for recurrent skull base tumours in order to
ascertain if it can be a real salvage approach.
Background: The management of recurrent skull base tumours can have a curative or pallia-
tive intent and mainly includes surgery and RT.
Materials and methods: One-thousand-ninety-one articles were found in the search databases
and the most relevant of them were analysed and briefly described.
Results: Data on recurrences of meningioma, pituitary adenoma, craniopharyngioma, chor-
doma  and chondrosarcoma, vestibular schwannoma, glomus jugulare tumours, olfactory
neuroblastoma and recurrences from head and neck tumours invading the base of skull
are reported highlighting the most relevant results in terms of local control, survival, sideRecurrence
Review
effects and complications.
Conclusions: In conclusion, it emerges that SRS and FSRT are effective and safe radiation
modalities of realize real salvage treatment for recurrent skull base tumours.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
cranial nerves, pituitary gland and inner and middle ears,1.  Background
The base of skull is a structure at the interface between the
intracranial content and the rest of the body where a num-
ber of neoplasms can arise from tissues of various origin
including bone, cartilage, soft tissues, muscles, lymphatic tis-
sue, nerves and nerve sheets, and embryonic remnants. This
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1507-1367/© 2014 Greater Poland Cancer Centre. Published by Elsevier explains the extremely large variety of benign and malignant
tumours occurring at this anatomic site. A peculiar aspect of
the skull base lesions is the proximity to structures deputed to
relevant physiologic functions like temporal lobes, brainstem,te Orientale”, Via Solaroli, 17 - 28100 Novara, Italy.
limiting extensive surgical approaches directed to achieve a
real radical oncologic result, otherwise possible in other body
districts.
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For these reasons, only the most recent progresses of
urgery and radiotherapy (RT) allowed to improve the results
n terms of local control with acceptable rates of side effects
nd complications.
Endoscopic surgery and neuro-navigation and high-
recision radiation techniques like stereotactic and intensity
odulated radiotherapy using photons and also particles
reatly contributed to the improvement of long term out-
omes. Despite the progress of the treatment modalities, the
ssue of local recurrence still remains the main cause of failure
n most of the skull base tumours.
The management of this type of tumour relapse can have
 curative or palliative intent and may include surgery, RT and
ometimes chemotherapy or a combination of them. A retreat-
ent is a challenge and should carefully take into account a
umber of factors related to the general status of the patient,
he extent of the disease, the previous treatments and the
atient’s preference.
In case of patient refusal or contraindications to surgery, a
adiation treatment should always be considered even in case
f previous irradiation. This can be a very challenging choice
onsidering a number of factors: (a) some tumours are radiore-
istant like sarcoma and chordoma; (b) they are often located
earby dose-limiting critical structures such as brainstem and
ptic pathway; (c) the previously delivered treatments, surgery
nd RT, can have altered the vascular and microvascular bed
f the region with hypo-oxygenation of the tissues including
he tumour itself that can result more  radioresistant.
When the tumour recurrence is of limited size, stereotac-
ic RT techniques offer relevant advantages: rapid decrease of
ose in the surrounding tissues, use of hypofractionation or
ingle ablative dose able to overcome the radioresistance.1 For
hese reasons, several authors employed radiosurgery (SRS),
.e. the single fraction, or fractionated stereotactic radiothe-
apy (FSRT) whenever possible.
.  Aim
n this review, we  present a critical analysis of the most
ecent available literature for the management of patients
ith tumour recurrence at the skull base and treated by stereo-
actic RT techniques.
.  Materials  and  methods
he following tumours were considered for the present review:
eningioma, pituitary adenoma, craniopharyngioma, chor-
oma and chondrosarcoma, vestibular schwannoma (VS),
lomus jugulare tumours (GJT), olfactory neuroblastoma (ON)
nd recurrences from head and neck tumours invading the
ase of skull.
Literature search was performed by Pubmed and Scopus by
sing the following words: skull base, recurrence, stereotactic
adiotherapy, radiosurgery and the name of tumour type. The
ime period was from 2000 to 2014. Articles reporting clinical
eries and review were included while case reports were in
rinciple excluded from the analysis.therapy 2 0 ( 2 0 1 5 ) 430–439 431
4.  Results
In total, 1091 articles were found and 66 were selected for the
analysis based on the relevance and the number of clinical
cases in relation to the frequency of the specific tumour type.
4.1.  Meningioma
The majority of intracranial meningiomas are benign
(90–95%), mainly arising from the base of skull and the others
are atypical and malignant mostly located in the convexities.2
Standard of care for benign meningioma is complete
surgery or subtotal resection followed by post-operative RT.
Several studies suggest that resected atypical and malignant
meningiomas should be treated with adjuvant RT, because
of the high recurrence rate.2,3 Actually, benign meningiomas
have long-term control rates up to 90% and atypical menin-
giomas up to 70% after combined approach.2
Most clinical series of skull base meningiomas report
results of SRS and FSRT for either adjuvant or salvage
treatment.4–12
Studies on SRS report local control rates of 90–100% and
cranial neuropathies in less than 8% of the cases.6,8,12 Interest-
ingly, local control decreases with tumour size while radiation
toxicity increases.8 One of the largest studies is from Flannery
et al. who analysed 168 patients treated with SRS for resid-
ual/recurrent meningiomas obtaining local control and overall
survival rates >90% at 5 years with relatively low incidence of
complications6 (Table 1).
FSRT offers a potential advantage for meningioma involv-
ing or directly adjacent to organs at risk and for larger tumour
volumes. Clinical data on FSRT show local control rates of
92–100% and toxicity in up to 9.8% of the cases4,7,9,10 (Table 1).
Cyberknife was used to deliver hypofractionated radiotherapy
in a series of 16 cases of skull base meningioma with similar
rates of local control and toxicity.11
Data on recurrent atypical and malignant meningiomas are
sparse with heterogeneous series. Mattozo et al. treated 25
recurrences with SRS and Sughrue et al. analysed 45 patients
with recurrent meningioma after surgery and adjuvant RT
who underwent a second surgery and brachytherapy implants
or gamma-knife SRS. These studies failed to show local control
or survival benefits.5,13 El-Khatib et al. analysed 14 patients
after incomplete resection or recurrence treated with SRS.
Tumour control rate at 3 years was 91% for atypical and 74% for
malignant meningiomas.14 Mori et al. studied 30 patients with
recurrent or residual atypical and malignant meningiomas
treated with SRS. Local control rate was 34% at 3 years.15
Pollock et al. treated 15 skull base atypical/malignant menin-
giomas with SRS (15 Gy) achieving a local control rate of 85%.16
Two studies described the use of stereotactic proton radio-
therapy for previously untreated and recurrent meningiomas
with local control rates of 88% and 94%, respectively.17,18
4.2.  Pituitary  adenomaPituitary adenomas represent 10–20% of all intracranial
tumours, and surgical resection is the preferred treatment for




































Table 1 – Selected series of recurrent skull base tumours treated by stereotactic radiotherapy.

























Minniti 20117 34/52 R FSRT






5.5% cranial nerve deficits
Shen 201210 69/224 R, RT FSRT
54  Gy, 27–30
fxs










R,  RT SRS
25 Gy




NA  22% hormone deficiencies
5.5% cranial nerve deficits
Sheehan 201125 418/418 (functioning
and
non-functioning)
R,  RT SRS
24 Gy






NA  24.4% hormone deficiencies




R,  RT SRS
16 Gy
36  mos 95% (5 yrs)
85% (10 yrs)




9% cranial nerve deficits
Craniopharyngioma

























Liu 200844 31/31 chordomas
(residual-recurrent)
R,  RT SRS
Gy
28 mos 64% (3 yrs)
21% (5 yrs)
OS







































Kano 201146 68/71 chordomas
(residual-recurrent)


































Hsu 201058 14/75 R SRS
14 Gy
98 mos 93% NA 12%  neurological deficits
Glomus jugulare tumours
Pollok 200464 23/42 NA SRS
Gy





Gerosa 200665 17/20 R, EE SRS
Gy




10%  hearing deterioration
Olfactory neuroblastoma







Recurrence from head and neck tumours invading the base of skull
Wu 200772 90/90 NPC RT ± CHT FSRT
18 Gy, 3 fxs
48 Gy, 6 fxs





















SRS, radiosurgery (marginal dose); FSRT, fractionated stereotactic radiotherapy; yrs, years; mos, months; R, resection; RT, radiotherapy; CHT, chemotherapy; P-32, intracavitary phosphorus-32
brachytherapy and cyst aspiration; EE, endovascular embolization; OS, overall survival; PFS, progression-free survival; DSS, disease specific survival; RFS, recurrence free survival; AREs, adverse
radiation effects; NCP, nasopharyngeal carcinoma; NA, not available.
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except for prolactinomas, which are usually treated medi-
cally. Surgical resection achieves tumour control in 50–80%
of cases. RT has a well-established role when surgical and
medical approaches have been exhausted.19
Salvage RT can be delivered by SRS or FSRT used in dif-
ferent settings. FSRT has the advantage of limiting radiation
damage to nearby radiation-sensitive structures such as the
optic apparatus, whereas SRS can be conveniently performed
in a single session with more  rapid biochemical remission.20
The majority of current research has been focused on
SRS and two large reviews including also recurrent disease
were recently published.21,22 The median margin dose of the
25 major SRS series on non-functioning adenomas, study-
ing 1935 patients, was 16 Gy. These studies achieved a mean
tumour control rate of 95.2% (range 83–100%). The occurrence
of hypopituitarism was observed in a mean 8.8% of patients
(range 0–40%). Among these studies, the multicentre trial of
Sheehan et al.,23 on residual/recurrent non-functioning ade-
nomas treated with gamma-knife SRS found a tumour control
rate >90% (Table 1).
Clinical series on secreting adenomas considered patients
with Cushing’s disease, acromegaly and hypersecretion of
prolactine.24,25 Series on Cushing’s disease analysing 646
patients treated with a median dose of 24 Gy (range
15–35), reported endocrine remission in a mean 51% of the
patients.21,22 Series on acromegaly analysing 1459 patients
treated with a median dose of 22 Gy (range 14–35), observed
endocrine remission in a mean 45% of the cases.22 Series on
prolactinomas, analysing 573 patients treated with a median
dose of 24 Gy (range 15–49), achieved endocrine remission in
a mean 35% of the patients.22 Endocrine remission in these
series required a time period from 3 months to 8 years. The
mean incidence of hypopituitarism was 18% (range 0–69%)
while cranial nerve dysfunction was observed in 4% of the
cases treated with gamma-knife with an increased risk cor-
related with the number of isocentres.
Data on proton SRS are also available. In a series of 22
patients with persistent acromegaly treated to a median dose
of 20 Gy (range 15–24 Gy), biochemical remission was observed
in 59% of the patients with median time to response of 42
months (range 6–62 months).26 Another series of 33 patients
with Cushing’s disease to a median dose of 20 Gy (range
15–20 Gy) showed hormone normalization in 52% of patients
with a median time of 18 months (range 5–49 months).27 Tox-
icity was represented by pituitary deficits in up to 52% of the
patients. Hypofractionated radiotherapy by Cyberknife was
used in patients with acromegaly reporting similar control
rates.28
4.3.  Craniopharyngioma
Craniopharyngiomas are rare tumours arising from Rathke’s
pouch. Treatment strategy includes gross total resection,
limited resection combined with RT, cystic drainage and intra-
tumour chemotherapy.
Gross tumour resection, achieving higher local control rate
compared with limited surgery (65–90% vs. 10–50%) is prefer-
ably performed in adults and children >5 years old, with
small tumours without hypothalamic invasion. Younger chil-
dren and patients with larger tumours should benefit from aiotherapy 2 0 ( 2 0 1 5 ) 430–439
conservative/partial surgical resection followed by postopera-
tive RT, in order to minimize neurological damage.29 Outcome
of multimodality approach is good, with 10-year local control
rates of 77–100% and 20-year overall survival of 66–92%.30
Even after radical surgery, local recurrence often occurs,
requiring additional treatments. Repeat surgery, however, is
associated with a greater risk of complications and a lower
cure rate,31 therefore the optimal approach for recurrent cran-
iopharyngioma is RT. In case of residual/recurrent tumours,
local control rates of 37% in larger lesions and of 87–94% in
smaller lesions are reported by using FSRT with 50–60 Gy and
SRS with a median marginal dose of 12–14 Gy, respectively.32–34
Neurological toxicity related to SRS, including visual deteri-
oration, endocrine morbidity and seizures, ranges from 0 to
19%32,33 (Table 1).
Cyberknife was used both in a single and in hypofrac-
tionated modalities for residual/recurrent craniopharyngioma
with a control rates of 91% at 2 years and 85% at 3 years and a
neurological toxicity in 0–4% of the patients.35,36
4.4.  Chordoma  and  chondrosarcoma
Chordomas and chondrosarcomas are rare and slow-growing
tumours arising in the skull base in 25–35% and 6% of cases,
respectively.37,38 A functional conserving surgery followed by
particle therapy is the most recommended treatment option,
and a recent review showed a local control and survival rates
at 5 years of 70% and 80% for chordomas and 75% and 99% for
chondrosarcomas.39 The patients, who experience recurrent
disease, are considered a challenge to physicians.
The published results, on the effectiveness of SRS in
patients with residual/recurrent chordomas and chodrosar-
comas of skull base, have been recently reviewed.40 The
authors41–47 of these articles on chordoma (158 patients) and
chondrosarcoma (48 patients) used a mean SRS margin dose
of 14 Gy (range 9–20 Gy). They achieved a mean tumour con-
trol rate at 5 years of 46% (range 15–72%) and of 87% (range
72–100%), and a survival rate at 5 years of 76–84% and of
70–100%, respectively for chordoma and chondrosarcoma. The
occurrence of adverse effects is reported in less than 10% of
the cases (Table 1).
Only few experiences48,49 evaluated FSRT. Bugoci et al.
treated 12 patients affected by skull base chordoma with adju-
vant or salvage FSRT. Median isocentre dose of 74 Gy (range
54–76 Gy) with conventional fractionation was delivered. Over-
all survival rate was 76.4% at 5 years.49
4.5.  Vestibular  schwannoma
VS are benign slow-growing tumours arising from the eighth
cranial nerve. The current treatment options are wait and see,
resection and RT.50
Actually there are no randomized studies evaluating com-
parative outcomes of surgery and RT. A recent meta-analysis
compared hearing and tumour outcome after treating small
(<3 cm)  VS with SRS and microsurgery: a better hearing func-
tion with SRS approach (70.2% vs. 50.3%, p < 0.001) and a similar
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The conservative approach (wait and see and RT at pro-
ression) is considered for patients almost asymptomatic with
25 mm tumours or with poor physical conditions.52
Residual tumour rate ranges between 2.6% and 6%, with-
ut significant differences among the different surgical
pproaches. A “less-than-total” resection of VS can be advo-
ated in order to preserve facial outcomes. Particularly for
atients with large (>3 cm maximum diameter) VS, a subto-
al resection is often performed, since RT can optimally arrest
ventual tumour regrowth.53 Even if partially resected, VS are
ften quiescent and inactive lesions, a significant recurrence
ate up to 44% has been reported in studies with long follow
p.54,55 The volume of residual tumours is the most important
rognostic variable for tumour regrowth.56
Two relevant studies on residual/recurrent VS employed
RS with single doses of 13.2 Gy and 14 Gy and reported a local
ontrol and rate >90%57,58 with progression free rate higher
or recurrent than for residual disease.58 Worsening of hear-
ng function was observed in up to 42% of patients57 (Table 1). A
eries of 386 patients treated by gamma-knife in single fraction
r cyberknife with hypofractionation is reported by Wowra
t al.59 with a failure rate in 7% and a serviceable hearing in
5% of patients.
.6.  Glomus  jugulare  tumours
JT are rare, indolent and highly vascularized lesions aris-
ng from the paraganglionic tissue of the IX–X cranial nerves.
reatment options include surgery, endovascular emboliza-
ion and RT alone or in combination with surgery.
Due the anatomic location of GJT, surgery is often sub-
ptimal and needs postoperative RT in case of persistence
nd recurrence. RT with standard fractionation schedule at a
ose of 45–50 Gy is considered as an optimal approach for pri-
ary  treatment or in case of residual/recurrent tumour after
urgery.60 Several studies reported tumour control outcomes
sing SRS similar or superior to those of standard fractionated
T, and with lower toxicity rate.40
Two metanalyses and a systematic review highlighted the
ffectiveness of SRS in the treatment of GJT, although method-
logical limitations due to the heterogeneity of the available
tudies limited the statistical significance.61–63
Data on two relevant series are reported in Table 1 showing
hat SRS is able to achieve local control in 97–100% of resid-
al/recurrent tumours with limited neurological toxicity.64,65
.7.  Olfactory  neuroblastoma
N is a rare neuroendocrine malignancy arising from the
lfactory neuroepithelium. The most frequently used treat-
ent approach is surgery followed by postoperative RT.66,67
espite this aggressive management, approximately 50% of
atients develop local recurrence and may require additional
reatments including surgery, RT and chemotherapy. Only
ew experiences on stereotactic RT are available for locally
ecurred ON.
In the study of Van Gompel et al., 8 patients were treated
y SRS with a median dose to the tumour margin of 15 Gy
chieving local control in 92% of the lesions68 (Table 1).therapy 2 0 ( 2 0 1 5 ) 430–439 435
4.8.  Recurrences  from  head  and  neck  tumours
invading  the  base  of  skull
Head and neck carcinomas are treated with aggressive multi-
modality therapies. However, about 50% with locally advanced
tumour experience a recurrent disease that may require new
treatments consisting of surgery, RT or chemotherapy or a
combination of them.69 Head and neck recurrences invad-
ing the skull base are a clinical challenge due to radiation
doses previously administered in proximity of critical struc-
tures. Stereotactic RT can be adopted as a salvage treatment
depending on the size and the location of the disease.
Chua et al. compared FSRT with SRS in a matched cohort
analysis.70 Fractionated SRT achieved better outcome espe-
cially for recurrent nasopharynx tumour in skull base and
less severe late complications: 33% in SRS group vs. 21% in
FSRT (Table 1). A few studies reporting different subsites of
relapse analysed overall 82 skull base recurrences.71–76 Total
dose ranged 20–59 Gy with daily fraction of 2.5–13 Gy. Overall
survival rates at 1 year were 38–78%. Severe late toxicity was
reported in some studies, but less frequently than in other
patients re-irradiated with conventional RT techniques.77 Of
note, Roh et al. reported 2 cases of skull base necrosis in 36
re-irradiations with FSRT with 3 fractions of 10–13 Gy.74
5.  Discussion
Stereotactic RT is a very precise and conservative treatment
modality used in several treatment settings including recur-
rent tumours at difficult sites.78,79 Thanks to the narrow
gradient dose at the periphery of the target volume, it can
safely deliver high RT dose to the target while sparing the
surrounding healthy tissue and critical organs nearby. Stereo-
tactic RT can be delivered in a single shot, as SRS, or in a
fractionated fashion as FSRT. The main difference resides in
the dose per fraction delivered to the target and to the sur-
rounding non-target tissues. We know from radiobiology that
a single high dose can be very effective in achieving tumour
control1 but, on the other hand, the repair of the sublethal
damage can be more  effective when a fractionated RT is deliv-
ered to an healthy tissue compared to a single high dose.
This fact can be crucial for minimizing the damage to late-
responding tissues such as the nervous structures that have
a low alpha/beta value in the linear-quadratic model. Clini-
cal data have confirmed these theoretic assumptions showing
that the side effects of SRS are more  severe than those of FSRT
especially when the target volume is abutting or compressing
a dose-sensitive critical structure. These data should drive the
choice of the best treatment option when a tumour recurrence
has to be considered for RT, especially in case of re-irradiation
(Figs. 1 and 2). In this regard, different dose constraints for
healthy structures can be used for SRT and FSRT, according
to the Quantitative Analyses of Normal Tissue Effects in the
Clinic (QUANTEC).80 Maximum dose should not exceed 10 Gy
for SRS and 55 Gy for FSRT to the optic pathway, 12–14 Gy for
SRS and 3–10 Gy for FSRT (3–10 fractions) to the inner ear and
cochlea, and 12.5 Gy for SRS and 54 for FSRT to the brainstem.
The data from the present literature review show that
both SRS and FSRT, when appropriately used, can be very
436  reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 430–439
Fig. 1 – Recurrent benign meningioma in a 47 years old male previously treated with partial surgery. (A) MRI  in axial view of
the residual meningioma after surgery at the level of the left cavernous sinus. (B) Axial view of the treatment plan showing
the isodose distribution of SRS to a dose of 14 Gy (prescribed to the 95% isodose). (C) MRI in axial view 3 years after
completion of SRS.
Fig. 2 – Pituitary adenoma in a 61 years old, male already treated with partial surgery. (A) MRI  in coronal view showing a
lesion extending to the parasellar region and abutting the chiasm. (B) Coronal view of the treatment plan showing the
isodose distribution of FSRT to a total dose of 18 Gy in 3 fractions of 6 Gy (prescribed to the 95% isodose). (C) MRI  in coronal
view 4 years after completion of FSRT.
effective and safe treatments in many  cases of tumour recur-
rence located in the base of skull.
SRS has been mainly used for small size residual/recurrent
meningioma, pituitary adenoma, craniopharyngioma, VS and
GJT (Table 1). In these cases, local control can be achieved
in more  than 90% of the patients especially in case of small
meningioma and VS.6,9,60 Neurological deficits range from
0% to about 10% depending on the anatomic location and
the size of the recurrence. As far as pituitary adenomas,
SRS can achieve more  favourable results in non-functioning
rather than hormone secreting tumours, that seem to be more
radioresistant.20,21 Less favourable result have been obtained
in case of chordoma and chondrosarcoma, most likely related
to the irregular shape and the larger size of the recurrence.42,43
FSRT usually with hypofractionated regimens has been
mainly employed in selected series of large size resid-
ual/recurrent meningioma and craniopharyngioma often
presenting with irregular shape. In these series local con-
trol can have large variations depending on the tumour
characteristics.7,10,30 In VS, FSRT is potentially better for
ear preservation compared to SRS, especially in case oflarge tumours.46 FSRT can be conveniently employed also in
selected cases of recurrent head and neck tumours invading
the base of skull.65,67 In general, FSRT should be preferred in
case of larger and irregularly shaped lesions when the preser-
vation of dose-limiting healthy tissues is the priority whereas
SRS can be conveniently used in case of small even radioresis-
tant lesions not abutting or compressing critical structures.
The main limitation of this literature review is related to
the available studies which are often retrospective and only
in few cases focused on recurrent tumours. In this regard,
most authors describe the results of the first treatment line
and report limited details about the pattern of recurrence, the
subsequent treatment modalities and the final outcome.
6.  ConclusionsSRS and FSRT are effective and safe radiation modalities to
realize a real salvage treatment for several recurrent skull base
tumours. The management of these challenging treatments
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re well represented including surgeons, radiation oncologists
nd medical oncologists and also pathologists and radiologist
ith a special expertise in skull base tumours. The decision
bout the final choice of treatment should always be taken
fter multidisciplinary discussion taking into account the pre-
ious medical history of the patient and his conditions and
ymptoms, the tumour characteristics and last but not least
he preference of the patient.




 e  f  e  r  e  n  c  e  s
1. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor
response to radiotherapy regulated by endothelial cell
apoptosis. Science 2003;300:1155–9.
2. Johnson J, Barani IJ. Radiotherapy for malignant tumors of
the skull base. Neurosurg Clin N Am 2013;24:125–35.
3. Stessin AM, Schwartz A, Judanin G, et al. Does adjuvant
external-beam radiotherapy improve outcomes for
nonbenign meningiomas? A Surveillance, Epidemiology, and
End Results (SEER)-based analysis. J Neurosurg
2012;117:669–75.
4. Milker-Zabel S, Zabel-du Bois A, Huber P, et al. Fractionated
stereotactic radiation therapy in the management of benign
cavernous sinus meningiomas. Strahlenther Onkol
2006;182:635–40.
5. Mattozo CA, De Salles AA, Klement IA. Stereotactic radiation
treatment for recurrent non benign meningiomas. J Neurosurg
2007;106:846–54.
6. Flannery TJ, Kano H, Lunsford LD, et al. Long-term control of
petroclival meningiomas through radiosurgery. J Neurosurg
2010;112:957–64.
7. Minniti G, Clarke E, Cavallo L, et al. Fractionated stereotactic
conformal radiotherapy for large benign skull base
meningiomas. Radiat Oncol 2011;6:36.
8. Bloch O, Kaur G, Jian BJ, et al. Stereotactic radiosurgery for
benign meningiomas. J Neurooncol 2012;107:13–20.
9. Pollock BE, Stafford SL, Link MJ, et al. Single fraction
radiosurgery of benign intracranial meningiomas.
Neurosurgery 2012;71:604–13.
0. Shen X, Andrews DW, Sergott RC, et al. Fractionated
stereotactic radiation therapy improves cranial neuropathies
in  patients with skull base meningiomas: a retrospective
cohort study. Radiat Oncol 2012;7:225.
1. Mahadevan A, Floyd S, Wong E, et al. Clinical outcome after
hypofractionated stereotactic radiotherapy (HSRT) for benign
skull base tumors. Comput Aided Surg 2011;16:112–20.
2. Starke RM, Williams BJ, Hiles C, et al. Gamma Knife surgery
for  skull base meningiomas. J Neurosurg 2012;116:588–97.
3. Sughrue ME, Sanai N, Shangari G, et al. Outcome and survival
following primary and repeat surgery for World Health
Organization Grade III meningiomas. J Neurosurg
2010;113:202–9.
3
therapy 2 0 ( 2 0 1 5 ) 430–439 437
4. El-Khatib M, El Majdoub F, Hoevels M, et al. Stereotactic
LINAC radiosurgery for incompletely resected or recurrent
atypical and anaplastic meningiomas. Acta Neurochir (Wien)
2011;153:1761–7.
5. Mori Y, Tsugawa T, Hashizume C, et al. Gamma Knife
stereotactic radiosurgery for atypical and malignant
meningiomas. Acta Neurochir Suppl 2013;116:85–9.
6. Pollock BE, Stafford SL, Link MJ, et al. Stereotactic
radiosurgery of WHO  grade II and III intracranial
meningiomas. Cancer 2012;118:1048–54.
7. Vernimmen FJ, Harris JK, Wilson JA, et al. Stereotactic proton
beam therapy of skull base meningiomas. Int J Radiat Oncol
Biol Phys 2001;49:99–105.
8. Halasz LM, Bussiere MR, Dennis ER, et al. Proton stereotactic
radiosurgery for the treatment of benign meningiomas. Int J
Radiat Oncol Biol Phys 2011;81:1428–35.
9. Hoybye C, Rahn T. Adjuvant gamma Knife radiosurgery in
non-functioning pituitary adenomas; low risk of long-term
complications in selected patients. Pituitary 2009;12:211–6.
0. Loeffler JS, Shih HA. Radiation therapy in the management of
pituitary adenomas. J Clin Endocrinol Metab 2011;96:1992–2003.
1. Amichetti M, Amelio D, Minniti G. Radiosurgery with photons
or  protons for benign and malignant tumours of the skull
base: a review. Radiat Oncol 2012;7:210.
2. Ding D, Starke RM, Sheehan JP. Treatment paradigms for
pituitary adenomas: defining the roles of radiosurgery and
radiation therapy. J Neurooncol 2014;117:445–57.
3. Sheehan JP, Starke RM, Mathieu D, et al. Gamma Knife
radiosurgery for the management of nonfunctioning pituitary
adenomas: a multicenter study. J Neurosurg 2013;119:446–56.
4. Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma Knife
surgery for Cushing’s disease. J Neurosurg 2007;106:980–7.
5. Sheehan JP, Pouratian N, Steiner L, et al. Gamma Knife
surgery for pituitary adenomas: factors related to radiological
and endocrine outcomes. J Neurosurg 2011;114:303–9.
6. Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic
radiosurgery in management of persistent acromegaly. Endocr
Pract 2007;13:726–34.
7. Petit JH, Biller BM, Yock TI, et al. Proton stereotactic
radiotherapy for persistent adrenocorticotropin-producing
adenomas. J Clin Endocrinol Metab 2008;93:393–9.
8. Roberts BK, Ouyang DL, Lad SP, et al. Efficacy and safety of
CyberKnife radiosurgery for acromegaly. Pituitary
2007;10:19–25.
9. Müller HL, Gebhardt U, Schroeder S, et al. Analyses of
treatment variables for patients with childhood
craniopharyngioma: results of the multicenter prospective
trial KRANIOPHARYNGEOM 2000 after three years of
follow-up. Horm Res Paediatr 2010;73:175–80.
0. Iannalfi A, Fragkandrea I, Brock J, et al. Radiotherapy in
craniopharyngiomas. Clin Oncol 2013;25:654–67.
1. Vinchon M, Dhellemmes P. Craniopharyngiomas in children:
recurrence, reoperation and outcome. Childs Nerv Syst
2008;24:211–7.
2. Kobayashi T. Long-term results of gamma Knife radiosurgery
for 100 consecutive cases of craniopharyngioma and a
treatment strategy. Prog Neurol Surg 2009;22:63–76.
3. Niranjan A, Kano H, Mathieu D, et al. Radiosurgery for
craniopharyngioma. Int J Radiat Oncol Biol Phys 2010;78:
64–71.
4. Jo KW, Shin HJ, Kong DS, et al. Treatment outcomes of
pediatric craniopharyngioma: a 15-year retrospective review
of  35 cases. J Korean Neurosurg Soc 2012;52:
37–41.5. Lee M, Kalani MY, Cheshier S, et al. Radiation therapy and
CyberKnife radiosurgery in the management of













































438  reports of practical oncology an
6. Iwata H, Tatewaki K, Inoue M, et al. Single and
hypofractionated stereotactic radiotherapy with CyberKnife
for  craniopharyngioma. J Neurooncol 2012;106:571–7.
7. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma:
incidence and survival patterns in the United States,
1973–1995. Cancer Cause Control 2001;12:1–11.
8. Lee SY, Lim YC, Song MH, et al. Chondrosarcoma of the head
and neck. Yonsei Med J 2005;46:228–32.
9. Uhl M, Welzel T, Oelmann J, et al. Active raster scanning with
carbon ions: reirradiation in patients with recurrent skull
base chordomas and chondrosarcomas. Strahlenther Onkol
2014;(March), http://dx.doi.org/10.1007/s00066-014-0608-2.
0.  Kano H, Lunsford LD. Stereotactic radiosurgery of intracranial
chordomas, chondrosarcomas, and glomus tumors. Neurosurg
Clin N Am 2013;24:553–60.
1. Krishnan S, Foote RL, Brown PD, et al. Radiosurgery for
cranial base chordomas and chondrosarcomas. Neurosurgery
2005;56:777–84.
2. Hasegawa T, Ishii D, Kida Y, et al. Gamma Knife surgery for
skull base chordomas and chondrosarcomas. J Neurosurg
2007;107:752–7.
3. Cho YH, Kim JH, Khang SK, et al. Chordomas and
chondrosarcomas of the skull base: comparative analysis of
clinical results in 30 patients. Neurosurg Rev 2008;31:35–43.
4. Liu AL, Wang ZC, Sun SB, et al. Gamma Knife radiosurgery for
residual skull base chordomas. Neurol Res 2008;30:557–61.
5. Koga T, Shin M, Saito N. Treatment with high marginal dose
is  mandatory to achieve long-term control of skull base
chordomas and chondrosarcomas by means of stereotactic
radiosurgery. J Neurooncol 2010;98:233–8.
6. Kano H, Iqbal FO, Sheehan J, et al. Stereotactic radiosurgery
for chordoma: a report from the North American gamma
Knife consortium. Neurosurgery 2011;68:379–89.
7. Iyer A, Kano H, Kondziolka D, et al. Stereotactic radiosurgery
for intracranial chondrosarcoma. J Neurooncol
2012;108:535–42.
8. Hauptman JS, Barkhoudarian G, Safaee M, et al. Challenges in
linear accelerator radiotherapy for chordomas and
chondrosarcomas of the skull base: focus on complications.
Int J Radiat Oncol Biol Phys 2012;83:542–51.
9. Bugoci DM, Girvigian MR, Chen JCT, et al. Photon-based
fractionated stereotactic radiotherapy for postoperative
treatment of skull base chordomas. Am J Clin Oncol
2013;36:404–10.
0. Mulder JJ, Kaanders JH, van Overbeeke JJ, et al. Radiation
therapy for vestibular schwannomas. Curr Opin Otolaryngol
Head Neck Surg 2012;20:367–71.
1. Maniakas A, Saliba I. Microsurgery versus stereotactic
radiation for small vestibular schwannomas: a meta-analysis
of patients with more  than 5 years’ follow-up. Otol Neurotol
2012;33:1611–20.
2. Ansari SF, Terry C, Cohen-Gadol AA. Surgery for vestibular
schwannomas: a systematic review of complications by
approach. Neurosurg Focus 2012;33:E14.
3. Gurgel R, Theodosopoulos V, Jackler R. Subtotala/near-total
treatment of vestibular schwannomas. Curr Opin Otolaryngol
Head Neck Surg 2012;20:380–4.
4. El-Kashlan HK, Zeitoun H, Arts HA, et al. Recurrence of
acoustic neuroma after incomplete resection. Am J Otol
2000;21:389–92.
5. Bloch DC, Oghalai JS, Jackler RK, et al. The fate of the tumor
remnant after less-than-complete acoustic neuroma
resection. Otolaryngol Head Neck Surg 2004;130:104–12.
6. Vakilian S, Souhami L, Melançon D, et al. Volumetric
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